At a glance
- Originator Boehringer Ingelheim Pharma KG
- Class Antiarrhythmics
- Mechanism of Action Muscarinic M2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 17 May 1997 Discontinued - Preclinical for Arrhythmias in Germany